Health Care [ 10/12 ] | Biotechnology [ 54/74 ]
NASDAQ | Common Stock
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.
It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia.
In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer.
The company has license and collaboration agreements with Pfizer Inc.; Servier; CellectisS. A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3.
The company was incorporated in 2017 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 24 | -0.35 Increased by +33.96% | -0.35 |
| May 13, 24 | -0.38 Increased by +44.12% | -0.41 Increased by +7.32% |
| Mar 14, 24 | -0.43 Increased by +34.85% | -0.45 Increased by +4.44% |
| Nov 2, 23 | -0.37 Increased by +36.21% | -0.52 Increased by +28.85% |
| Aug 2, 23 | -0.53 Decreased by -1.92% | -0.59 Increased by +10.17% |
| May 3, 23 | -0.68 Decreased by -21.43% | -0.62 Decreased by -9.68% |
| Feb 28, 23 | -0.66 Decreased by -22.22% | -0.70 Increased by +5.71% |
| Nov 2, 22 | -0.58 Decreased by -1.75% | -0.64 Increased by +9.38% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by -100.00% | -66.29 M Decreased by -8.12% | - - |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -66.36 M Increased by +14.91% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 22.00 K Decreased by -57.69% | -65.00 M Increased by +33.90% | Decreased by -295.45 K% Decreased by -56.23% |
| Dec 31, 23 | 21.00 K Decreased by -55.32% | -85.78 M Increased by +8.08% | Decreased by -408.47 K% Decreased by -105.72% |
| Sep 30, 23 | 43.00 K Decreased by -12.24% | -61.31 M Increased by +25.36% | Decreased by -142.59 K% Increased by +14.94% |
| Jun 30, 23 | 44.00 K Decreased by -48.84% | -77.99 M Decreased by -4.72% | Decreased by -177.25 K% Decreased by -104.69% |
| Mar 31, 23 | 52.00 K Decreased by -14.75% | -98.34 M Decreased by -23.37% | Decreased by -189.11 K% Decreased by -44.73% |
| Dec 31, 22 | 47.00 K Decreased by -7.84% | -93.32 M Decreased by -24.65% | Decreased by -198.55 K% Decreased by -35.25% |